Tag: Brukinsa for follicular lymphoma

Home / Brukinsa for follicular lymphoma

Categories

Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma

March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refra...
brukinsa-for-follicular-lymphoma

Scan the code